Skip to main content

Companies at CUBEInC

Industry

Precision Genetics logoPrecision Genetics is a biotechnology company specializing in molecular diagnostic testing and software as a service in the area of pharmacogenomics. Testing modalities including PCR, capillary electrophoresis, and next-generation sequencing (NGS), which are used to provide critical information on a patient's ability to metabolize and tolerate medications including pain medications (e.g., opioids, NSAIDs), cardiovascular medications (e.g., statins, anticoagulants, antiplatelets), psychotropic medications (e.g., antidepressants, antipsychotics) and many others. Precision Genetics has two laboratories, one in the Upstate at CubeInc and the second is in Charleston, SC. We work with large hospital systems and private clinics to help ensure that medications are prescribed responsibly with both safety and efficacy in mind.

Exciting news: We have recently launched our pharmacogenomic testing solutions at Clemson University (RedFern Health) along with several prominent healthcare networks in the Upstate and Lowcountry of South Carolina. We have also worked hard to dramatically expand our network of insurance coverage within the state for 2024. Precision Genetics is a research-driven company that sponsors and participates in clinical trials around the country, aiming to improve the scope and implementation of precision medicine in the United States.

Elastrin Therapeutics logoElastrin Therapeutics is a US and UK-based biotech startup developing novel therapies to reverse chronic cardiovascular and lung diseases. Its underlying technology was developed by Prof. Vyavahare during the last 20 years at Clemson University. The team consists of seven experts and has built a proprietary platform that can restore vascular health by removing pathological calcification and restoring elastin damage. This is achieved by targeting drug-loaded nanoparticles directly to the diseased tissue where elastin has been degraded using the company’s proprietary antibody. Elastrin’s lead product will be tested in clinical trials starting in 2024 and become commercially available in 2027.

Recently, here at Elastrin Therapeutics, we have moved lab spaces to double our R&D production. We now have increased our capabilities to add additional groundbreaking technologies. These technologies will allow us to more efficiently produce a product that can quickly be scaled-up and brought to a clinical trial. This new lab space and equipment will support our vision of reversing tissue and organ calcification, which will, in turn, save billions of lives.

Samaritan Biologics logoSamaritan Biologics is a regenerative medicine company based in Memphis, Tennessee, with the tagline: Helping, Healing, Giving. Samaritan Biologics is partnered with AATB-accredited tissue banks and medical device companies to develop future healing solutions that include perinatal tissue grafts, cadaveric allografts, and biomaterial grafts. Samaritan Biologics has recently obtained wet lab space at CUBEInC, enabling Samaritan to continue to develop and evaluate next-generation, best-in-class human allografts, biomaterials and biologic products in collaboration with world-class clinicians and scientists.

NeuroHope Therapeutics logoNeuroHope Therapeutics, Inc. is a start-up company pursuing the development and commercialization of a proprietary polymer-based drug delivery system invented by Dr. Jeoung Soo Lee at Clemson University. Through a combination of material design and delivery route, their technology can provide targeted delivery of different types of pharmaceuticals, alone or in combination. This approach allows them to achieve therapeutic doses in local tissues, while minimizing systemic side effects. In addition, NeuroHope’s delivery carrier is a platform technology that can be applied to a wide range of drugs and disease conditions. The first product is intended to treat acute spinal cord injury, providing patients with improved recovery of motor and sensory function.

Recent News:

  • Academic startup Grant awarded from South Carolina Research Authority (SCRA) on June 2023
  • NIH STTR phase I proposal in NINDS is pending
  • Participated Redefining Early Stage Investments (RESI) conference (https://resiconference.com/) in Atlanta on Mar 25-27.

Website: https://www.neurohopetherapeutics.com